The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of the first interim analysis of the CARMA study to investigate efficacy and safety profile of catumaxomab in clinical practice.
Volker Kunzmann
Consultant or Advisory Role - Consultant
Honoraria - Honoraria for presentations
Jalid Sehouli
Consultant or Advisory Role - Consultant
Honoraria - Honoraria for presentations
Barbara Schmalfeldt
Consultant or Advisory Role - Consultant
Honoraria - Honoraria for presentations
Pauline Wimberger
Consultant or Advisory Role - Consultant
Honoraria - Honoraia for presentations
Christian M. Kurbacher
Research Funding - Funding
G.-F. Tempelhoff
Research Funding - Funding
Udo J. Vanhoefer
Research Funding - Funding
P. Ebeling
Research Funding - Funding
F. Breuer
Research Funding - Funding
Holger Schulz
Research Funding - Funding
Manfred Welslau
Research Funding - Funding
Dominique Finas
Consultant or Advisory Role - Consultant
Honoraria - Funding
Jaqueline Sagasser
Research Funding - Funding
M. Kiehl
Research Funding - Funding
S. Fruehauf
Research Funding - Funding